Beata Wolska-Kuśnierz1, Hanna Gregorek2, Krystyna Chrzanowska3, Barbara Piątosa4, Barbara Pietrucha5, Edyta Heropolitańska-Pliszka5, Małgorzata Pac5, Maja Klaudel-Dreszler6, Larysa Kostyuchenko7, Srdjan Pasic8, Laszlo Marodi9, Bernd H Belohradsky10, Peter Čižnár11, Anna Shcherbina12, Sara Sebnem Kilic13, Ulrich Baumann14, Markus G Seidel15,16, Andrew R Gennery17, Małgorzata Syczewska18, Bożena Mikołuć19, Krzysztof Kałwak20, Jan Styczyński21, Anna Pieczonka22, Katarzyna Drabko23, Anna Wakulińska24, Benjamin Gathmann25, Michael H Albert26, Urszula Skarżyńska5, Ewa Bernatowska5. 1. Department of Immunology, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. bwolska@interia.pl. 2. Department of Microbiology and Clinical Immunology, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. 3. Department of Medical Genetics, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. 4. Histocompatibility Laboratory, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. 5. Department of Immunology, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. 6. Gastrology, Hepatology Department, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. 7. Western-Ukrainian Centre of Paediatric Immunology, Western Ukrainian Specialized Children's Medical Centre, Dnisterska Street, 27, Lviv, 79035, Ukraine. 8. Pediatric Immunology, Mother and Child Health Institute, Medical School, University of Belgrade, Radoja Dakica 6-8, 11070, Belgrade, Serbia. 9. Department of Infectious and Pediatric Immunology, Medical and Health Science Center, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary. 10. University Childrens Hospital, Ludwig Maximilians University, Lindwurmstrasse 4, 80337, Munich, Germany. 11. 1st Pediatric Department, Comenius University Medical Faculty, Children University Hospital, Mickiewiczova 13th, Bratislava, 813 69, Slovakia. 12. Department of Сlinical Immunology and Allergy, Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, 1 Samori Mashela Str., Moscow, 117917, Russia. 13. Department of Paediatric Immunology, Uludag University School of Medicine, Özlüce Mh., 16120, Bursa, Turkey. 14. Department of Pediatric Pulmonology and Neonatology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. 15. Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria. 16. Division of Pediatric Hematology-Oncology, Department of Pediatric and Adolescent Medicine, Medical University Graz, Auenbruggerplatz 38, 8036, Graz, Austria. 17. Institute of Cellular Medicine, Child Health, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. 18. Department of Paediatric Rehabilitation, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. 19. Department of Pediatrics and Developmental Disorders of Children and Adolescents, Medical University Bialystok, 15-089 Jana Kilinskiego str. 1, Białystok, Poland. 20. Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, 50-368 Bujwida Str. 44, Wroclaw, Poland. 21. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, 85-094 Curie-Skłodowskiej 9 str., Bydgoszcz, Poland. 22. Department of Pediatric Hematology, Oncology and Haematopoietic Stem Cell Transplantation, University of Medical Sciences, Poznań, 60-572 Szpitalna str. 27/33, Poznań, Poland. 23. Department of Pediatric Hematology, Oncology and Transplantology, Medical University, Lublin, 20-093 W. Chodźki str. 2, Lublin, Poland. 24. Department of Oncology, Children's Memorial Health Institute, 04-730 Av. Dzieci Polskich 20, Warsaw, Poland. 25. Centre of Chronic Immunodeficiency, University Medical Center Freiburg and University of Freiburg, Robert-Koch-Str. 1, 79106, Freiburg, Germany. 26. Department of Pediatric Hematology/Oncology, Dr. von Hauner University Children's Hospital, Lindwurmstraße 4, 80337, Munich, Germany.
Abstract
PURPOSE: Nijmegen Breakage Syndrome (NBS) is a rare inherited condition, characterized by microcephaly, chromosomal instability, immunodeficiency, and predisposition to malignancy. This retrospective study, characterizing the clinical and immunological status of patients with NBS at time of diagnosis, was designed to assess whether any parameters were useful in disease prognosis, and could help determine patients qualified for hematopoietic stem cell transplantation. METHODS: The clinical and immunological characteristics of 149 NBS patients registered in the online database of the European Society for Immune Deficiencies were analyzed. RESULTS: Of the 149 NBS patients, 91 (61%), of median age 14.3 years, remained alive at the time of analysis. These patients were clinically heterogeneous, with variable immune defects, ranging from negligible to severe dysfunction. Humoral deficiencies predisposed NBS patients to recurrent/chronic respiratory tract infections and worsened long-term clinical prognosis. Eighty malignancies, most of lymphoid origin (especially non-Hodgkin's lymphomas), were diagnosed in 42% of patients, with malignancy being the leading cause of death in this cohort. Survival probabilities at 5, 10, 20 and 30 years of age were 95, 85, 50 and 35%, respectively, and were significantly lower in patients with than without malignancies. CONCLUSIONS: The extremely high incidence of malignancies, mostly non-Hodgkin's lymphomas, was the main risk factor affecting survival probability in NBS patients. Because treatment of NBS is very difficult and frequently unsuccessful, the search for an alternative medical intervention such as hematopoietic stem cell transplantation is of great clinical importance.
PURPOSE: Nijmegen Breakage Syndrome (NBS) is a rare inherited condition, characterized by microcephaly, chromosomal instability, immunodeficiency, and predisposition to malignancy. This retrospective study, characterizing the clinical and immunological status of patients with NBS at time of diagnosis, was designed to assess whether any parameters were useful in disease prognosis, and could help determine patients qualified for hematopoietic stem cell transplantation. METHODS: The clinical and immunological characteristics of 149 NBSpatients registered in the online database of the European Society for Immune Deficiencies were analyzed. RESULTS: Of the 149 NBSpatients, 91 (61%), of median age 14.3 years, remained alive at the time of analysis. These patients were clinically heterogeneous, with variable immune defects, ranging from negligible to severe dysfunction. Humoral deficiencies predisposed NBSpatients to recurrent/chronic respiratory tract infections and worsened long-term clinical prognosis. Eighty malignancies, most of lymphoid origin (especially non-Hodgkin's lymphomas), were diagnosed in 42% of patients, with malignancy being the leading cause of death in this cohort. Survival probabilities at 5, 10, 20 and 30 years of age were 95, 85, 50 and 35%, respectively, and were significantly lower in patients with than without malignancies. CONCLUSIONS: The extremely high incidence of malignancies, mostly non-Hodgkin's lymphomas, was the main risk factor affecting survival probability in NBSpatients. Because treatment of NBS is very difficult and frequently unsuccessful, the search for an alternative medical intervention such as hematopoietic stem cell transplantation is of great clinical importance.
Authors: R Varon; E Seemanova; K Chrzanowska; O Hnateyko; D Piekutowska-Abramczuk; M Krajewska-Walasek; J Sykut-Cegielska; K Sperling; A Reis Journal: Eur J Hum Genet Date: 2000-11 Impact factor: 4.246
Authors: Helen V New; C M Cale; M Tischkowitz; A Jones; P Telfer; P Veys; A D'Andrea; C G Mathew; I Hann Journal: Pediatr Blood Cancer Date: 2005-05 Impact factor: 3.167
Authors: R Varon; C Vissinga; M Platzer; K M Cerosaletti; K H Chrzanowska; K Saar; G Beckmann; E Seemanová; P R Cooper; N J Nowak; M Stumm; C M Weemaes; R A Gatti; R K Wilson; M Digweed; A Rosenthal; K Sperling; P Concannon; A Reis Journal: Cell Date: 1998-05-01 Impact factor: 41.582
Authors: T C Yeo; D Xia; S Hassouneh; X O Yang; D E Sabath; K Sperling; R A Gatti; P Concannon; D M Willerford Journal: Mol Immunol Date: 2000-12 Impact factor: 4.407
Authors: Igor B Resnick; Irina Kondratenko; Oleg Togoev; Natalia Vasserman; Irena Shagina; Oleg Evgrafov; Svetlana Tverskaya; Karen M Cerosaletti; Richard A Gatti; Patrick Concannon Journal: J Pediatr Date: 2002-03 Impact factor: 4.406
Authors: Jay P Patel; Jennifer M Puck; Rajgopal Srinivasan; Christina Brown; Uma Sunderam; Kunal Kundu; Steven E Brenner; Richard A Gatti; Joseph A Church Journal: J Clin Immunol Date: 2015-02-13 Impact factor: 8.317
Authors: Elena Deripapa; Dmitry Balashov; Yulia Rodina; Alexandra Laberko; Natalya Myakova; Nataliia V Davydova; Maria A Gordukova; Dmitrii S Abramov; Galina V Pay; Larisa Shelikhova; Andrey P Prodeus; Mikhail A Maschan; Alexey A Maschan; Anna Shcherbina Journal: Front Immunol Date: 2017-07-24 Impact factor: 7.561
Authors: James Slack; Michael H Albert; Dmitry Balashov; Bernd H Belohradsky; Alice Bertaina; Jack Bleesing; Claire Booth; Jochen Buechner; Rebecca H Buckley; Marie Ouachée-Chardin; Elena Deripapa; Katarzyna Drabko; Mary Eapen; Tobias Feuchtinger; Andrea Finocchi; H Bobby Gaspar; Sujal Ghosh; Alfred Gillio; Luis I Gonzalez-Granado; Eyal Grunebaum; Tayfun Güngör; Carsten Heilmann; Merja Helminen; Kohei Higuchi; Kohsuke Imai; Krzysztof Kalwak; Nubuo Kanazawa; Gülsün Karasu; Zeynep Y Kucuk; Alexandra Laberko; Andrzej Lange; Nizar Mahlaoui; Roland Meisel; D Moshous; Hideki Muramatsu; Suhag Parikh; Srdjan Pasic; Irene Schmid; Catharina Schuetz; Ansgar Schulz; Kirk R Schultz; Peter J Shaw; Mary A Slatter; Karl-Walter Sykora; Shinobu Tamura; Mervi Taskinen; Angela Wawer; Beata Wolska-Kuśnierz; Morton J Cowan; Alain Fischer; Andrew R Gennery Journal: J Allergy Clin Immunol Date: 2017-04-07 Impact factor: 10.793
Authors: Aleksandra Lewandowicz-Uszyńska; Gerard Pasternak; Jerzy Świerkot; Katarzyna Bogunia-Kubik Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622